No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 – 99
Sex
Any
Study type
Observational
Participants needed
8,000 (estimated)
Sponsor
AstraZeneca · Industry
Who this trial is looking for
This trial is looking for asthma patients who have used albuterol and are considering adjusting their treatment. Participants will compare two different treatment approaches to see which is more effective in preventing severe asthma episodes.
Are You a Good Fit for This Trial?
You may be able to join if
I have been diagnosed with asthma.
I am at least 18 years old.
I have taken albuterol in the past 12 months.
I have a prescription for Airsupra or low-dose ICS or LTRA since January 2023.
I have had continuous health insurance coverage for the past 12 months.
You may not be able to join if
I have been treated for any chronic respiratory condition or systemic inflammatory disease in the past 12 months.
I have taken any inhaled corticosteroids or other asthma medications in the past 12 months.
I have used maintenance oral corticosteroids in the past 12 months.
I have a SABA prescription on the same date as my Airsupra prescription.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
The QUARTZ study is a retrospective observational cohort study using a prevalent new-user design and U.S. healthcare claims data to evaluate treatment effectiveness among patients with asthma. The study compares the real-world effectiveness of switching from albuterol-only rescue therapy to albuterol/budesonide versus adding low-dose inhaled corticosteroids (ICS) or leukotriene receptor antagonist…
The QUARTZ study is a retrospective observational cohort study using a prevalent new-user design and U.S. healthcare claims data to evaluate treatment effectiveness among patients with asthma. The study compares the real-world effectiveness of switching from albuterol-only rescue therapy to albuterol/budesonide versus adding low-dose inhaled corticosteroids (ICS) or leukotriene receptor antagonists (LTRA) while continuing albuterol. The primary objective is to assess the comparative effectiveness of these treatment strategies in reducing severe asthma exacerbations in routine clinical practice in the United States.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Asthma patients with at least one prescription record (identified by NDC or Healthcare Common Procedure Coding System \[HCPCS\] codes) for Airsupra (Airsupra cohort), LD ICS or LTRA, (comparator cohort) since January 2023.
* Patients with at least one prescription record (base…
Inclusion Criteria:
* Asthma patients with at least one prescription record (identified by NDC or Healthcare Common Procedure Coding System \[HCPCS\] codes) for Airsupra (Airsupra cohort), LD ICS or LTRA, (comparator cohort) since January 2023.
* Patients with at least one prescription record (based on NDC or HCPCS codes) of albuterol within the 12 months prior to the first Airsupra or the controller medications prescription date
* Patients aged ≥18 years on the index date
* Patients with ≥12 months of continuous insurance enrolment prior and 12 months after index date.
Exclusion Criteria:
* Patients with at least one medical claim with an ICD-10 code within the 12 months prior to the index date for any of the chronic respiratory conditions or systemic inflammatory diseases routinely treated with systemic corticosteroids (SCS)
* Patients with any prescription record for any ICS or other controller therapies (including SAMA, LABA, LAMA, LTRA, theophylline or biologics) within the 12 months prior to the and inclusive of index date (the index therapy defining cohort entry (LD ICS for the LD ICS cohort; LTRA for the LTRA cohort is permitted on the index date)
* Patients with maintenance OCS use within the 12 months prior to and inclusive of the index date
* Airsupra patients with a concomitant SABA prescription record on the index date
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.